A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age

Respiratory Distress Syndrome, Newborn Clinical Trial

Official title:

A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of Lucinactant for Inhalation Versus nCPAP Alone in Preterm Neonates 26 to 32 Weeks Gestational Age With RDS

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04264156
• Other study ID #: 03-CL-1702
• Status: Terminated
• Phase: Phase 2
• Start date: April 18, 2020
• Est. completion date: March 28, 2021

Study information

• Verified date: April 2023
• Source: Windtree Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to evaluate the safety and efficacy of lucinactant for inhalation in conjunction with nCPAP, in comparison to nCPAP alone, in preterm neonates with RDS, as assessed by the incidence of and time to respiratory failure and/or death due to RDS in the first 72 hours and 28 days of life. Half of the subjects will receive lucinactant for inhalation and half will receive standard of care (nCPAP alone).

Description:

An unmet medical need exists for a means to deliver surfactant replacement therapy (SRT) to preterm neonates with RDS supported with nCPAP early in the course of the disease. This strategy has the potential to improve RDS prior to the development of respiratory failure, thereby avoiding the need for endotracheal intubation and mechanical ventilation (MV), or reduce the duration of MV, and the resultant potential for morbidity and complications. The ability to administer SRT via aerosol has the potential to address this unmet need. Lucinactant for inhalation (AEROSURF) is an investigational drug-device combination product, designed to deliver aerosolized SRT to preterm neonates with RDS who are being supported with nCPAP. The drug component of lucinactant for inhalation is lyophilized lucinactant, a lyophilized form of SURFAXIN® (lucinactant) Intratracheal Suspension. The device component, the AEROSURF Delivery System (ADS), the next-generation device following use of the prototype device in earlier trials, uses novel technology to aerosolize lucinactant for inhalation. This study evaluates the safety and efficacy of lucinactant for inhalation in conjunction with nCPAP, in comparison to nCPAP alone, in preterm neonates with RDS, as assessed by pre-specified outcome measures. In addition, this study will evaluate the device and the ability to administer up to 3 repeat doses.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: March 28, 2021
• Est. primary completion date: January 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Minutes to 6 Hours

Eligibility

Inclusion Criteria:

• Signed ICF from legally authorized representative.
• Gestational age: 26 to 32+6 weeks PMA.
• Successful implementation of non-invasive support or ventilation within 30 minutes after birth.
• Spontaneous breathing.
• Investigator determination of RDS. A chest x-ray should be obtained before treatment to confirm the diagnosis.
• Within the first 6 hours after birth, requires an nCPAP of 5 to 7 cm H2O that is clinically indicated for at least 15 minutes with an FiO2 > 0.25 to = 0.35 to maintain SpO2 of 90% to 95%.

Exclusion Criteria:

• A heart rate that cannot be stabilized above 100 bpm within 5 minutes of birth.
• Recurrent episodes of apnea requiring positive pressure ventilation.
• A 5 minute Apgar score < 5.
• Major congenital malformation(s) or craniofacial abnormalities that preclude the use of nCPAP.
• Clinically significant diseases or conditions other than RDS which could potentially interfere with cardiopulmonary function.
• A known or suspected chromosomal abnormality or syndrome.
• Premature rupture of membranes > 3 weeks.
• Hemodynamic instability requiring vasopressors or steroids for hemodynamic support and/or presumed clinical sepsis.
• A need for intubation and/or invasive mechanical ventilation at any time before enrollment into the study.
• The administration (or plan for administration) of another investigational agent or investigational medical device, any other surfactant agent, or systemic corticosteroids.
• Presence of air leak on the baseline chest radiograph or diagnosed via ultrasound or illumination.

Related Conditions & MeSH terms

• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn

Intervention

Combination Product:
• Lucinactant for Inhalation
A drug-device combination product that delivers aerosolized SRT to preterm neonates with RDS who are being supported with nasal continuous positive airway pressure (nCPAP).

Other:
• nCPAP Only
Nasal continuous positive airway pressure (nCPAP) alone

Locations

Country	Name	City	State
Poland	Szpital Specjalistyczny nr 2 w Bytomiu Oddzial Noworodkow Blok Va	Bytom
Poland	Ginekologiczno-Polozniczy Szpital Kliniczny Uniwewersytetu Medycznego im. Karola Marcinkowskiego	Poznan
Poland	Samodzielny Publiczny Spcjalistyczny Zaklad Opieki Zdrowotnej "Zdroje", Oddzial Noworodkow	Szczecin

Sponsors (1)

Lead Sponsor	Collaborator
Windtree Therapeutics

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Respiratory Failure or Death	Number of participants with respiratory failure due to RDS or death. Respiratory failure due to RDS is defined as intubation for mechanical ventilation and/or surfactant administration	28 days of life
Secondary	Number With BPD	Number of participants with bronchopulmonary dysplasia (BPD)	36 weeks post-menstrual age (PMA)
Secondary	Mortality	All-cause mortality	36 weeks PMA or 28 days of life (whichever is later)
Secondary	Number of Participants With Common Complications of Prematurity	Number of participants with complications including intraventricular hemorrhage, periventricular leukomalacia, pulmonary hemorrhage, apnea, necrotizing enterocolitis, patent ductus arteriosus, acquired sepsis, and retinopathy of prematurity.	36 weeks PMA